Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adverum Biotechnlgs (NQ: ADVM )

0.8275 +0.0188 (+2.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 284,853
Open 0.8011
Bid (Size) 0.8012 (12)
Ask (Size) 0.8599 (69)
Prev. Close 0.8087
Today's Range 0.7813 - 0.8290
52wk Range 0.5310 - 2.340
Shares Outstanding 98,125,866
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?
Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during... 
Via Benzinga
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE

Performance

YTD
+29.30%
+29.30%
1 Month
-14.76%
-14.76%
3 Month
-53.51%
-53.51%
6 Month
-38.70%
-38.70%
1 Year
+25.38%
+25.38%

More News

Read More
Over $14M Bet On Diversified Healthcare Trust? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Adverum Posts New Data From Wet AMD Gene Therapy Trial
Via Benzinga
Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022
Via Benzinga
Adverum's Data at ASGCT Further Supports Phase 2 Development Plans For Wet-AMD Gene Therapy
Via Benzinga
Adverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
Via Benzinga
Adverum Commences Mid-Stage Chronic Eye Disorder Candidate Study
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: FDA Signs Off Cancer Therapy Trials For NexImmune, Omega Therapeutics, Endo To Develop Rare Hereditary Skin Disease Candidate
Via Benzinga
The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
Via Benzinga
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
Via Benzinga
Short Volatility Alert: Adverum Biotechnologies, Inc.
Via Benzinga
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
Via Benzinga
3 Stocks Under $3 Insiders Are Aggressively Buying
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.